Accessibility Menu

Freenome(NASDAQ) FRNM

Market Cap$1.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+47%
5 YearN/A
1 Year+40%
1 Month+33%
$14.77
-0.14%
-0.02Today
After hours$14.77+$0.00 (+0.00%)
Freenome last closing stock price
MetricPriceDate
Last closeUSD 14.792026-08-31
Freenome stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.33%USD 13.782026-08-24
1 month+32.65%USD 11.152026-07-31
3 month+33.48%USD 11.082026-06-02
Year to date+13.51%USD 13.032025-12-31
1 year+39.8%USD 10.582025-08-29
Since inception+47.16%USD 10.052024-06-12

Freenome Financials at a Glance

Market Cap

$1.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$0.76

EPS (TTM)

-$0.07

P/E Ratio

-212.20

Dividend

$0.00

Beta (Volatility)

0.13 (Low)

Price

$14.77

Volume

770,301.808

Open

$14.63

Previous Close

$14.79

Daily Range

$14.28 - $14.81

52-Week Range

$9.95 - $15.09

Estimated Earnings Date

Jul 15, 2026

FRNM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Freenome

Freenome, Inc. is a biotechnology company focused on developing innovative solutions for early cancer detection through its proprietary multi-omics platform. The company aims to transform cancer care by providing accurate and accessible diagnostic tools.

Products and Services
  • Multi-omics platform for early cancer detection
  • Comprehensive blood tests to identify cancer biomarkers
  • Partnerships with healthcare providers for diagnostic integration
Growth Outlook
  • Strong market demand for early cancer detection solutions
  • Expanding partnerships with leading healthcare institutions
  • Potential for significant revenue growth as product adoption increases
Financial Highlights
  • Market capitalization of approximately $112.65 million
  • Stock price range between $9.95 and $14.47 over the past year
  • Low beta of 0.348 indicates stability compared to the overall market
Freenome, Inc. operates in a rapidly evolving sector with a strong emphasis on early cancer detection, which is increasingly recognized as vital for improving patient outcomes. The company's innovative approach and technology position it well within the biotechnology industry. With a solid market capitalization and a stable stock price, Freenome presents an intriguing opportunity for investors interested in the healthcare sector. The focus on partnerships and product development suggests a promising trajectory for future growth.
AI Generated • Aug 24, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Aaron Elliott, PhD

Website

www.perceptivelife.com/pcsc

Headquarters

Brisbane, CA 94005, US

FRNM Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-91.65%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-0.47%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$1.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

107.45M

Volume

770.30K

Avg. Volume

513.07K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Freenome Performance Analysis

Freenome annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Freenome annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD 0.17N/A
20252025-12-31USD 0.08-56.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$1.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$37.40

N/A

Employees

3

N/A

Net Income

-$0.11

-0.2%

EBITDA

-$0.94

+4.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$0.44

-67.5%

Total Debt

$0.00

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-86.06%

-0.2%

Return on Invested Capital

1.59%

+0.7%

Free Cash Flow

-$0.13

+0.9%

Operating Cash Flow

-$0.13

+0.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About FRNM

What is the current price of Freenome?

Freenome is trading at $14.79 per share.

What is the 52-week range for Freenome?

Over the past 52 weeks, Freenome has traded between $9.95 and $15.09.

How much debt does Freenome have?

As of the most recent reporting period, Freenome reported total debt of $0.00.

How much cash does Freenome have on hand?

Freenome reported $437.37K in cash and cash equivalents in its most recent financial results.

What is Freenome’s dividend yield?

Freenome does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services